Scarborough Biotechnology LTD

The healthcare, pharmaceutical, and medical industries are investing heavily in cutting-edge software solutions and smarter machine learning and artificial intelligence technology. The full benefits of this tech revolution may lead to a revolution in disease treatment and extend the healthspan of millions of patients, according to those experts.

According to recent statistics, information technology budgets are increasing across the country, but experts say the healthcare IT spending, ...

Visualizing data is an important part of understanding the data.

In the latest version of Snapshot, scientists can now see visual representations of gene expressions through the visual analytics function, said Macauley Coggins, director of Scarborough Biotechnology. Snapshot is the company’s premier software solution that allows genome-scale model of human metabolism.

“We think that building this visualization feature will make studying g...

When you think genetic engineering, you tend to think of large companies and well-funded research laboratories. But, with breakthroughs such as CRISPR becoming more common, smaller companies and teams now have the same access to the power of genetic engineering that once was only in the hands of these labs and big companies.

However, genetic engineering tools and equipment is still expensive. But, that was before the disruptive power of Snapshot came along.

Scarborough ...

Update 1.3.0 is probably the largest update to come to Snapshot so far by adding 18 genes, 8 reactions, and 14 metabolites as well as a host of improvements to metabolite prediction. 

Current model:

• 73 Genes
• 38 Reactions
• 85 Metabolites
• 3 Cellular Compartments
• ...

Introduction

According to Genetic Disorders UK.org there are between 4,000 to 6,000 diagnosed genetic disorders ranging from common disorders such as sickle cell disease (1 in 500 africans) to more rare disorders such as lactate dehydrogenase A deficiency which has a prevelance of only 1 in 1 milion. Given the amount of potential disorders there is a push for more rapid yet accurate diagnosis for patients. 

With new cutting edge pharmaceuticals relying heavily on recombinant proteins there has been a big push by bioprocessing companies to optimise and increase production of recombinant proteins. These proteins are typically produced in bacterial cells such as e-coli and for more complex proteins mamalian cell lines such as CHO.

However growing proteins in mamalian cells like CHO is challenging as they require optimal en...